Aegea Medical said last week it tapped former Cardiokinetix prez & CEO Maria Sainz as its new president and chief executive officer, effective immediately. Sainz will replace former CEO Don Gurskis, who has held the corner office since 2013. Gurskis will remain on as member of the Redwood City, Calif.-based company’s executive management team. “Maria is […]
Cardiac Dimensions said today that it raised a $39 million Series B round for the Carillon mitral valve repair device it’s developing. Kirkland, Wash.-based Cardiac Dimensions said the round was led by a new Australian backer, Hostplus, and included a venture debt contribution from Oxford Finance. Existing investors M. H. Carnegie, Arboretum Ventures, Lumira Capital, LSP Health […]
Cardiac Dimensions said today that the FDA granted an investigational device exemption for a pivotal trial of its Carillon mitral valve repair device. Kirkland, Wash.-based Cardiac Dimensions said the 400-patient study will compare the device with guideline-directed treatment of symptomatic functional mitral regurgitation associated with heart failure after a year. The percutaneous Carillon annuloplasty device is designed […]
Cardiac Dimensions today touted the publication of a small study of its Carillon mitral valve repair system in the Journal of Invasive Cardiology, saying the device led to significant improvement in patients with functional mitral regurgitation. The percutaneous Carillon annuloplasty device is designed to use a distal anchor and proximal anchor, connected by a shaping ribbon, to reshape the […]
Cardiac Dimensions said this week that it tapped the former chief of AccessClosure, Gregory Casciaro, to be its new president & CEO. Casciaro led AccessClosure until its May 2014 acquisition by Cardinal Health (NYSE:CAH) for $320 million. His résumé includes stints as the chief executive at drug-eluting stent maker Xtent, Orquest (acquired JNJ’s DePuy Acromed in 2003) […]
Cardiac Dimensions said yesterday a new cost-utility study of its Carillon mitral valve shows it to be a cost-effective alternative when compared to optimal medical treatment for treating functional mitral regurgitation. The study was published in the journal BMC Cardiovascular Disorders, and analyzed data from the Titan clinical trial. The study reported an incremental cost-effectiveness ratio […]
Cardiac Dimensions today said it launched a clinical trial of its Carillon device, which is designed to treat functional mitral valve regurgitation. The 120-patient Reduce FMR study is a prospective, double-blind, randomized multi-center trial, Kirkland, Wash.-based Cardiac Dimensions said. Patients are slated to be randomized on a 3:1 basis to receive the Carillon device and optimal drug […]
Cardiac Dimensions today said it raised another $15.2 million for its Carillon mitral valve implant, taking the total of its most recent funding round to $43 million.